Seer, Inc.

NASDAQ•SEER

CEO: Dr. Omid C. Farokhzad M.D., Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2020-12-04

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Contact Information

3800 Bridge Parkway, Suite 102, Redwood City, CA, 94065, United States

650-453-0000

seer.bio

Market Cap

$101.25M

P/E (TTM)

-1.4

19.9

Dividend Yield

52W High

$2.41

52W Low

$1.62

52W Range

23%

Rank54Top 78.1%

2.7

F-Score

Modified Piotroski Analysis

Based on 7-year fundamentals

Weak • 2.7 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2019-2025

Financial Dashboard

Q4 2025 Data

Revenue

$4.20M+0.00%

4-Quarter Trend

EPS

-$0.29+0.00%

4-Quarter Trend

FCF

-$11.10M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Revenue Increased 17% Total revenue reached $16.6M in 2025, up 17% ($2.4M increase), driven by higher product sales and service revenue.

Gross Profit and Loss Improvement Gross profit grew 20% to $8.5M; Net loss improved 15% to $(73.6M), reflecting reduced operating expenses.

Operating Expenses Significantly Reduced Total operating expenses decreased 19% to $86.5M, primarily due to 25% reduction in SG&A expenses ($14.0M decrease).

Proteograph ONE Throughput Gains Third-generation Proteograph ONE assay launched in May 2025, delivering 3.6x throughput increase over previous assay versions.

Risk Factors

Continued Operating Losses Expected Company has incurred significant losses since 2017; expects to continue incurring net losses and negative cash flows near term.

Market Acceptance Uncertainty Commercial success hinges on broad scientific and market acceptance of Proteograph, which may take longer than anticipated.

Intellectual Property Enforcement Risk Reliance on patents; challenges or failure to enforce IP rights could allow competitors to commercialize similar products.

Reliance on Key Customers Related party revenue was 5% of total revenue in 2025; loss of key customers could materially impact financial results.

Outlook

Drive Installed Base Utilization Focus on driving higher utilization and consumable pull-through from the rapidly expanding installed base across all customer types.

Expand Population-Scale Cohorts Announced several population-scale studies in 2025; actively discussing expansion with additional key biobanks globally.

Leadership in AI Biology Platform Pursue strategic ecosystem partnerships to establish leadership as preferred proteomic data platform for AI-driven discovery.

New Product Innovation Focus Aim to continuously innovate and develop new products, applications, and analysis tools across the R&D value chain.

Peer Comparison

Revenue (TTM)

GLUE

$181.54M

+1112.3%

NRIX

$83.98M

+54.0%

KYMR

$39.20M

-16.7%

Gross Margin (Latest Quarter)

KYMR

2763.6%

-2680.7pp

LYEL

100.0%

+0.0pp

CCCC

83.6%

+13.4pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
KYMR	$6.91B	-23.4	-29.1%	4.7%
PHVS	$1.74B	-8.7	-67.1%	0.2%
NRIX	$1.37B	-5.7	-57.5%	8.1%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-0.0%

Flat Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 11, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data